Retinol_COA_27758_MedChemExpress
《溶血磷脂酸对胃癌细胞的增殖迁移作用及其信号通路》范文
《溶血磷脂酸对胃癌细胞的增殖迁移作用及其信号通路》篇一一、引言胃癌是一种常见的消化道恶性肿瘤，其发病率和死亡率均居高不下。
溶血磷脂酸（Lysophosphatidic Acid，LPA）作为一种生物活性脂质，在细胞增殖、迁移等生物学过程中起着重要作用。
近年来，关于LPA在胃癌细胞中的作用及其信号通路的研究逐渐成为热点。
本文旨在探讨溶血磷脂酸对胃癌细胞的增殖迁移作用及其信号通路，以期为胃癌的治疗提供新的思路和方向。
二、溶血磷脂酸的结构与功能溶血磷脂酸是一种重要的生物活性脂质，具有多种生物学功能。
它参与细胞膜的构建和维持，同时也是多种生物活性分子的前体。
在细胞内，LPA通过与细胞膜上的G蛋白偶联受体结合，激活下游信号通路，从而影响细胞的增殖、迁移、分化等生物学过程。
三、溶血磷脂酸对胃癌细胞的作用研究表明，LPA对胃癌细胞的增殖和迁移具有显著的影响。
在胃癌细胞中，LPA能够促进细胞的增殖和迁移，同时抑制细胞的凋亡。
这一过程涉及到多种信号通路的激活，如MAPK、PI3K/AKT等。
这些信号通路的激活进一步促进了胃癌细胞的生长和转移。
四、溶血磷脂酸信号通路的研究LPA对胃癌细胞的增殖迁移作用主要通过激活其信号通路实现。
目前研究认为，LPA主要通过G蛋白偶联受体（GPR）介导的信号通路发挥作用。
在胃癌细胞中，LPA与GPR结合后，激活MAPK、PI3K/AKT等信号分子，进而促进细胞的增殖和迁移。
此外，LPA还可能通过其他信号通路影响胃癌细胞的生物学行为，如Wnt/β-catenin等。
五、信号通路的调控与干预针对LPA信号通路的调控与干预是治疗胃癌的重要策略之一。
目前的研究表明，通过抑制LPA信号通路中的关键分子，如MAPK、PI3K/AKT等，可以抑制胃癌细胞的增殖和迁移。
此外，针对GPR的拮抗剂也可以有效地抑制LPA对胃癌细胞的作用。
这些研究成果为胃癌的治疗提供了新的思路和方向。
六、结论本文探讨了溶血磷脂酸对胃癌细胞的增殖迁移作用及其信号通路。
乳腺癌组织中褪黑素受体MTl和CUEDC2的表达及临床意义
Ｅ ｐ ｅｓ ｎｏ ｌｔｎｎ ｒｃｐｏ （ １ ａ ｄ Ｃ Ｅ ｄ ｍａｎ ｃｎ ａ ｉｇ２ Ｃ Ｅ ２ ｎｈ ｍａ ｒａｔ ａ ｃｒ ｘ ｒｓｉ ｆ ｏ ｍｅ ｏ ｉ ｅｅ ｔｒ ＭＴ ） ｎ Ｕ ｏ ｉ－ｏ ｔｉ ｎ （ Ｕ ＤＣ ）ｉ ｕ ｎｂ ｅｓ ｃ ｎ ｅ ａ ｎ
２ ２ １ 江 苏镇 江 江 苏大 学基 础 医学 与 医学技术 学 院 １０３
曾 建 ，陈丽 萍 ，陈 淼 ，许 豪勤 ，陈 艳 ，刘 克 坚 ，狄 荣科
【 摘
要】 目的
检测乳腺癌 组织 中褪黑素受体 （ Ｔ ） Ｃ Ｅ结构域 蛋 白 ２ Ｃ Ｅ Ｃ ） Ｍ １与 Ｕ （ Ｕ Ｄ ２ 的表达 ， 讨二 者表达 的相关 探
ｎ ｍ１ ｒａｔ ｉ ｕ ｅｅ ８ ８ ．０ ０ ａ ｄ １ ． ％ ｗ ｔ ｓ ｔ ｔ ａ ｓ ｎｆ ａ ｃ （ ０ ０ ） ｈ ｏｉ ｖ ｘ ｒｓｉ ｔ ｏ Ｕ Ｄ ２ ０ ａ ｂｅ ｓ ｔ ｓｅｗ ｒ ７ ． ％ ６ ． ％ ｎ ６ ７ ｌ ｓ ｉ ｔ ｉ ｉ ｌ ｉ ｉ ｃｎ ｅ Ｐ＜ ． ５ ．Ｔ ｅｐ ｓ ｉｅ ｐｅ ｓ ｎｒ ｅ ｆ Ｅ Ｃ ｈ ａ ｓｃ ｇ ｉ ｔ ｅ ｏ ａ Ｃ
ａ ｌｎ ｃ ｌｓｇ ｆｃ ｎ ｅ ｎｄ ｃ ｉ ｉ ａ ｉ ｎｉ ａ ｃ ｉ
Ｚ Ｎ ｉｎ Ｈ Ｎ Ｌ－ｉｇ，Ｃ Ｅ Ｍｉｏ Ｘ ｏｑｎ Ｈ Ｎ Ｙ ｎ， Ｉ ｅ ｉｎ Ｉ ｏｇｋ ．Ｃ ｌｇ Ｅ Ｇ Ｊ ，Ｃ Ｅ ｉ ｎ ａ ｐ Ｈ Ｎ ａ ， Ｕ Ｈａ —ｉ ，Ｃ Ｅ ａ ＬＵ Ｋ －ａ ，Ｄ ｎ —ｅ ｏｌ ｅｏ ｊ Ｒ ｅ ｆ Ｍｅｉ ｌ ｃ ｎｅａ ｄＬ ｂｒｔ ｙＭｅｉ ｎ ａ ｇｕ Ｕ ｉ ｒｔ ， ｅｊ ｎ １０ ３ Ｃ ｉ ｄｃ ｉ ｃ ｎ ａ ｏａｏ ｄｃ ｅｏ Ｊ ｎ ｓ ｎｖ ｓｙ ｎｉ ｇ ２ ２ １ ， ｈｎ ａ Ｓｅ ｒ ｉ ｆｉ ｅｉ ａ ａ
RP-HPLC测定人血清中黄连素浓度
ΡΠ-ΗΠΛΧ测定人血清中黄连素浓度张宏文 邵志高 孙一勤Ξ江苏省人民医院药研室 南京提 要 运用反相高效液相色谱法测定了人血清中黄连素浓度∀以改性甲醇为流动相 检测波长为 外标法定量 线性范围为 ∗ Ù ρ 平均回收率为 最低检测限 日内 日间误差均小于 ∀方法灵敏 准确 快速 可用于药代动力学和药效学的研究∀关键词 高效液相色谱法 黄连素 血药浓度分类号 Ù前言近来研究表明 黄连素是一种安全 有效的抗心律失常药 但其量效关系尚不清楚 且盐酸黄连素不宜肌注和静滴给药 否则可能引起阿斯综合症 过敏性休克等 ∀有关黄连素血药浓度的测定 国外研究甚少 国内也不多∀为此 有必要建立黄连素的模型 研究黄连素在体内的药物动力学参数 定量分析阐明黄连素的剂量与效应间的规律 给临床合理用药提供客观依据∀因此 我们首次建立了人血清黄连素的测定方法∀此法具有快速 灵敏 准确 经济等优点∀实验部分仪器与试药仪器 瑞典 型高效液相色谱仪紫外检测器 进样阀 型液体快速混合器 江西医疗器械厂型离心沉淀器 上海手术器械厂 ∀试剂 甲醇 乙腈 二氯甲烷 三乙胺均为 级试剂 水为二次重蒸水∀药品 盐酸黄连素 成都军区制药厂 ∀方法与结果黄连素标准贮备液 Ù 精确称取相当于黄连素 的盐酸黄连素置于 容量瓶中 用甲醇溶解并稀释至刻度 置于冰箱内保存∀临用时用甲醇稀释至所需浓度∀色谱条件 色谱柱 ≅流动相为甲醇 三乙胺 Ú ςÙς 流速Ù 纸速 Ù 检测波长 灵敏度 室温 ∗ ε∀测定方法 取含药血清 置于 具塞试管中∀加乙腈 二氯甲烷 密塞∀在快速混匀器上振荡 离心 Ù ∀精确吸取有机层 置于尖底刻度试管中 在水浴中 ε氮气流下挥干 残渣用 Λ 甲醇溶解 进样 Λ ∀色谱分离结果 图 是本实验条件下空白血清 含药血清的典型色谱图∀黄连素保留时间为能与血清杂质峰很好的分离∀图 小檗碱分离色谱图Φιγ Χηρο ατογρα οφβερβερινε空白血清 血清样品∀线性范围与最低检测限 取空白血清 加黄连素标准液配成Ù 血清∀按测定方法项操作 以峰高对浓度回归 得回归方程Η Χ ν ρΠ ∀黄连素最低检测限为 信噪比大于 ∀回收率与精密度 分别取空白血清 精确加入第 卷第 期色 谱年 月Ξ江苏省职工医科大学药学专业实习生本文收稿日期 修回日期黄连素标准液 配成 Ù 个浓度∀按测定方法项操作 以空白血清中加入标准液后经提取测得的样品峰高与标准溶液直接进样测得的峰高比计算回收率 结果见表 和表 ∀表 人血清中黄连素回收率 νΤαβλε Ρεχοϖερψρατεοφβερβερινινσερυ ν浓度 Ù回收率平均回收率 Σ∆表 人血清中黄连素精密度Ταβλε Τηε ρχεισιονοφδετερ ινατιονοφβερβερινινσερυ浓 度Ù 日内误差 ΞΣ∆ν ΡΣ∆ 日间误差 Ξ^Σ∆ν ΡΣ∆讨论色谱条件的选择 流动相中三乙胺浓度的变化对黄连素的保留时间和理论塔板数的影响较大∀随着三乙胺浓度的增加 保留时间下降 理论塔板数增大∀为了保证既有较高的柱效 又有适宜的保留时间 本文选用三乙胺浓度为 ∀我们选择干扰小 灵敏度足够大的 为检测波长∀曾用乙醚 乙酸乙酯 氯仿Ú异丙醇 Ú 二氯甲烷等不同溶剂提取 以二氯甲烷回收率为最高表 ∀本文测定一个样品仅需 具有快速灵敏 操作简便 杂质干扰少等特点 可用于药代动力学和药效学研究∀表 不同溶剂下黄连素回收率Ταβλε Τηερεχοϖερψρατεοφβερβερινινδιφφερεντσολϖεντ提取溶剂 回收率乙 醚 乙酸乙酯 氯仿 异丙醇Ú 二氯甲烷参考文献蒋永培 朱新民 中国医院药学杂志 戴自英 刘裕昆 汪 复 临床抗菌药物学 北京 人民卫生出版社沈克温 王绪明 韩永平 实用药物分离鉴定手册 北京 人民军医出版社∆ετερ ινατιονοφΒερβερινεινΗυ ανΣερυ βψΡεϖερσεδ-ΠηασεΗιγηΠερφορ ανχεΛιθυιδΧηρο ατογρα ηψϑιανγσυΠροϖινχεΗοσ ιταλ ΝανϕινγΑβστραχτ ≅ Ù ρΚεψωορδσ期 张宏文等 测定人血清中黄连素浓度。
反相高效液相梯度洗脱法同时测定鼻泰滴鼻液中的3组分
反相高效液相梯度洗脱法同时测定鼻泰滴鼻液中的3组分夏曙辉;滕英博;张秋红;李黎;宋炳生【期刊名称】《华西药学杂志》【年(卷),期】2004(19)1【摘要】目的建立鼻泰滴鼻液中盐酸麻黄碱、山莨菪碱及地塞米松磷酸钠的含量测定方法。
方法采用RP -HPLC法 ,以梯度洗脱 ,色谱柱为SymmetryC18柱(2 5 0mm× 4 .6mm ,5 μm) ,流动相A为0 0 2mol·L-1磷酸二氢钾缓冲液 (0 3%三乙胺磷酸调pH 3 0 ) ;流动相B为乙腈 ,梯度条件为6→ 15min ,乙腈12 %→ 5 5 % ;流速1 2ml·min-1,检测波长为 2 2 0nm。
结果盐酸麻黄碱、山莨菪碱和地塞米松磷酸钠在此条件下实现基线分离 ,3组分线性范围分别为 3 1～ 0 0 2 5、0 8～ 0 0 0 5、1 2～0 0 0 3mg·ml-1(r=0 9999) ;平均回收率分别为 99 5 2 % (RSD =1 34% )、98 94 % (RSD =1 6 3% )、10 0 4 % (RSD =1 76 % )。
结论所用方法简便快速、结果准确可靠 ,适用于该复方制剂中 3组分的同时测定。
【总页数】2页(P56-57)【关键词】反相高效液相梯度洗脱法;测定;鼻泰滴鼻液;盐酸麻黄碱;山莨菪碱;地塞米松磷酸钠【作者】夏曙辉;滕英博;张秋红;李黎;宋炳生【作者单位】南京军区南京总医院【正文语种】中文【中图分类】R987;R927.1【相关文献】1.高效液相梯度洗脱法同时测定复方诺氟沙星滴耳液中3组分的含量分析 [J], 吕文辉2.高效液相梯度洗脱法同时测定复方诺氟沙星滴耳液中3组分的含量分析 [J], 吕文辉;3.高效液相梯度洗脱法同时测定复方诺氟沙星滴耳液中3组分的含量 [J], 朱雪松;黄雪靖;廖婧;郑芳4.反相高效液相梯度洗脱法测定地松磺胺麻黄碱滴鼻液中有效成分含量 [J], 娄月芬;张健;唐跃年;李莉霞;叶琦5.高效液相梯度洗脱法同时测定复方诺氟沙星滴耳液中3组分的含量分析 [J], 吴佳佳;周晓慧因版权原因，仅展示原文概要，查看原文内容请购买。
高效液相色谱法测定灯盏花素片中灯盏花乙素的含量(英文)
高效液相色谱法测定灯盏花素片中灯盏花乙素的含量(英文)戚爱棣
【期刊名称】《中草药》
【年(卷),期】2003(34)4
【摘要】目的建立高效液相色谱法测定灯盏花素片中灯盏花乙素的含量。
方法色谱柱Diam onsil C1 8( 4.6 mm× 15 0 mm,5 μm) ,流动相 :乙腈 - 0 .5 %乙酸溶液( 2 2∶ 78) ,检测波长 :335 nm,柱温:30℃ ,流速 :1.2 m L/min。
结果灯盏花乙素线性范围为 0～6 .0μg,加样回收率为 10 0 .43%,RSD为 0 .5 8%。
结论该方法简便、快速、准确 ,可用于灯盏花素片的质量控制。
【总页数】3页(P322-324)
【关键词】高效液相色谱法;测定;灯盏花素片;灯盏花乙素
【作者】戚爱棣
【作者单位】天津中医学院中药系
【正文语种】中文
【中图分类】R286.0
【相关文献】
1.RP-HPLC测定灯盏花素分散片中灯盏花乙素的含量 [J], 张晓喻;李琪;杨必坤;刘刚;张宏
2.高效液相色谱法测定灯盏花素片中灯盏花乙素含量 [J], 王群共;何选林
3.HPLC法测定灯盏花素片中灯盏花乙素的含量 [J], 傅海鸥;张凤敏;刑继芳
4.高效液相色谱法测定灯盏花素分散片中灯盏乙素的含量 [J], 邹薇;何国华;魏东峰
5.反相高效液相色谱法测定灯盏花素滴丸中灯盏乙素的含量 [J], 桂双英;周亚球因版权原因，仅展示原文概要，查看原文内容请购买。
华中科技大学学术期刊分类目录(T-D)_最新权威版
24.755 23.917 23.654 23.565 23.333 23.194 22.929 22.864 22.864 22.864 22.490 22.345 22.333 21.757 21.543 21.543 20.833 20.761 20.614 19.966 19.795 19.547 19.352 18.571 18.571 18.038 17.983 17.983 17.949 17.689 17.689 17.689 17.436 17.313 17.215 16.417 16.238 16.179 16.008 16.008 15.766 15.575 15.518 15.389 15.389 15.389 15.333 15.333 15.280 15.280 15.265 15.253 15.251 15.202
ONCOLOGY CLINICAL NEUROLOGY PLANT SCIENCES BIOCHEMICAL RESEARCH METHODS ASTRONOMY & ASTROPHYSICS MATERIALS SCIENCE, MULTIDISCIPLINARY PHYSICS, MULTIDISCIPLINARY BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY MEDICINE, RESEARCH & EXPERIMENTAL MICROBIOLOGY PHARMACOLOGY & PHARMACY PHYSICS, PARTICLES & FIELDS CHEMISTRY, MULTIDISCIPLINARY PHARMACOLOGY & PHARMACY TOXICOLOGY CHEMISTRY, MULTIDISCIPLINARY CELL BIOLOGY NEUROSCIENCES INFECTIOUS DISEASES IMMUNOLOGY PHYSIOLOGY PHYSICS, MULTIDISCIPLINARY BEHAVIORAL SCIENCES NEUROSCIENCES ONCOLOGY CELL BIOLOGY DEVELOPMENTAL BIOLOGY ECOLOGY CHEMISTRY, MULTIDISCIPLINARY MAபைடு நூலகம்ERIALS SCIENCE, MULTIDISCIPLINARY NANOSCIENCE & NANOTECHNOLOGY GENETICS & HEREDITY MICROBIOLOGY MEDICINE, GENERAL & INTERNAL MICROBIOLOGY ASTRONOMY & ASTROPHYSICS MATERIALS SCIENCE, MULTIDISCIPLINARY BEHAVIORAL SCIENCES NEUROSCIENCES NEUROSCIENCES PSYCHOLOGY CLINICAL NEUROLOGY ECOLOGY EVOLUTIONARY BIOLOGY GENETICS & HEREDITY CHEMISTRY, PHYSICAL PHYSICS, CONDENSED MATTER BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY PSYCHOLOGY MEDICINE, GENERAL & INTERNAL NEUROSCIENCES CARDIAC & CARDIOVASCULAR SYSTEMS
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
高效液相色谱法测定胃乐胶囊中硫酸阿托品含量
高效液相色谱法测定胃乐胶囊中硫酸阿托品含量李德潮【摘要】目的：建立测定胃乐胶囊中硫酸阿托品含量的高效液相色谱（HPLC）法。
方法色谱柱为Kromasil C18柱（250 mm ×4.6 mm，5μm），流动相为0.05 mol/L磷酸二氢钠溶液（用磷酸调节pH至2.8）－乙腈（90：10），柱温为30℃，流速为1.0 mL/min，检测波长为210 nm。
结果硫酸阿托品质量浓度在10.0~100.0μg/mL范围内与峰面积呈良好线性关系，平均回收率为98.88%，RSD为0.50%( n=6)。
结论该方法准确、灵敏、重复性好，可作为胃乐胶囊的质量控制方法。
%Objective To establish an HPLC method for the determination of atropine sulfate in Weile Capsules. Methods The chro-matographic column was the Kromasil C18 column(250 mm × 4. 6 mm,5μm)at the temperature of 30 ℃,with 0. 05 mol/L sodium di-hydrogen phosphate solution(adjusting pH to 2. 8 with phosphoric acid)-acetonitrile(90 :10) as the mobile phase and detected with UV 210 nm and the flow rate of 1. 0 mL/min. Results The Atropine Sulfate in the range of 10. 0-100. 0 μg/m L showed good lin-ear relatiomship with the peakarea,the average recovery rate was 98. 88%,RSD=0. 50% ( n=6 ) . Conclusion This method is accurate,sensitice and reproducible,which canbe used for the determination of atropine sulfate in Weile Capsules.【期刊名称】《中国药业》【年(卷),期】2016(025)002【总页数】2页(P68-69)【关键词】高效液相色谱法;胃乐胶囊;硫酸阿托品;含量测定【作者】李德潮【作者单位】广西医科大学制药厂，广西南宁 530021【正文语种】中文【中图分类】R284.1;R286.0胃乐胶囊为复方制剂，由氢氧化铝、白及、颠茄流浸膏等组方，具有行气止痛、收敛生肌、促进溃疡愈合的功效，临床用于治疗胃胀闷疼痛、嗳气泛酸、恶心呕吐、食少、疲乏无力、大便不畅等疾病，收载于《卫生部药品标准·中药成方制剂(第十七册)》。